Insider Transactions in Q1 2017 at Merck & Co., Inc. (MRK)
Insider Transaction List (Q1 2017)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2017
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,795
+11.78%
|
$181,675
$65.85 P/Share
|
|
Feb 27
2017
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
3,758
+8.54%
|
$244,270
$65.85 P/Share
|
|
Feb 27
2017
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
31,913
+50.0%
|
$2,074,345
$65.85 P/Share
|
|
Feb 27
2017
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
11,771
+24.59%
|
$765,115
$65.85 P/Share
|
|
Feb 27
2017
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
101,552
+14.47%
|
$6,600,880
$65.85 P/Share
|
|
Feb 27
2017
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,707
+7.93%
|
$240,955
$65.85 P/Share
|
|
Feb 27
2017
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
16,995
+13.76%
|
$1,104,675
$65.85 P/Share
|
|
Feb 27
2017
|
Michael J Holston EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,159
+16.3%
|
$790,335
$65.85 P/Share
|
|
Feb 27
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,797
+16.2%
|
$181,805
$65.85 P/Share
|
|
Feb 27
2017
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
32,670
+24.33%
|
$2,123,550
$65.85 P/Share
|
|
Feb 27
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
39,970
+50.0%
|
$2,598,050
$65.85 P/Share
|
|
Feb 14
2017
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Open market or private sale
|
Direct |
2,954
-20.19%
|
$189,056
$64.73 P/Share
|
|
Feb 08
2017
|
Patricia F Russo Director |
SELL
Open market or private sale
|
Direct |
5,000
-27.55%
|
$320,000
$64.42 P/Share
|
|
Feb 08
2017
|
Patricia F Russo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+21.6%
|
$175,000
$35.19 P/Share
|
|
Feb 07
2017
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
10,125
-1.99%
|
-
|
|
Feb 06
2017
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$320,000
$64.51 P/Share
|
|
Feb 06
2017
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$255,000
$51.86 P/Share
|
|
Feb 03
2017
|
Thomas R Cech Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$315,000
$63.42 P/Share
|
|
Feb 03
2017
|
Thomas R Cech Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$175,000
$35.19 P/Share
|
|
Feb 03
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
36,335
-100.0%
|
$2,289,105
$63.73 P/Share
|
|
Feb 03
2017
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
36,335
+35.96%
|
$1,271,725
$35.03 P/Share
|
|
Feb 03
2017
|
Michael J Holston EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
91,959
-35.32%
|
$5,793,417
$63.84 P/Share
|
|
Feb 03
2017
|
Michael J Holston EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
77,959
+24.31%
|
$4,599,581
$59.04 P/Share
|
|
Feb 03
2017
|
Wendell Peter C Director |
SELL
Open market or private sale
|
Direct |
15,000
-93.75%
|
$945,000
$63.69 P/Share
|
|
Feb 03
2017
|
Wendell Peter C Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.5%
|
$480,000
$32.51 P/Share
|